Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707552 | 1.00 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL20647500 | 0.99 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21707763 | 0.99 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23263493 | 0.98 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23263569 | 0.97 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21707797 | 0.96 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21707829 | 0.96 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL21707754 | 0.95 | MAPT (0.35) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23263491 | 0.94 | MAPT (0.32) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23264105 | 0.94 | MAPT (0.33) | MAPTMEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-20200048232-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048232-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, CYP1A1 | MAPT 1909/4885MEN1 268/4885KMT2A 1805/4885 |
| US-11718606-B2 | Polycyclic compound and organic light emitting element comprising same | CRY1, CRY2, CYP1A1 | MAPT 1909/4885MEN1 268/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.